Starboard Value · conference-presentation
Pfizer Inc. (PFE)
74 pages · 3 arc beats · 2 loops
Pfizer Inc. (PFE)
Starboard Value · 2024-10 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
151015202530354045505560657074
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 72 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem (Identify pain) 8 slides 100% 8/8 slides 100% 8/8 slides · 52 hits — 0/8 slides
62.5% 5/8 slides 87.5% 7/8 slides 100% 8/8 slides 100% 8/8 slides · 9 hits Agitate (Make it worse) 50 slides 100% 50/50 slides 100% 50/50 slides · 308 hits — 0/50 slides
10% 5/50 slides 72% 36/50 slides 100% 50/50 slides 100% 50/50 slides · 100 hits Solution (Provide relief) 14 slides 100% 14/14 slides 100% 14/14 slides · 83 hits — 0/14 slides
— 0/14 slides
85.7% 12/14 slides 100% 14/14 slides 92.9% 13/14 slides · 26 hits Slide inventory
74 every slide · same image gating as the playbook
03
The slide uses a three-column layout to segment the portfolio, highlighting key brands within each.establish_context
04
Uses authority-citation framework via news headlines to validate the claim.summarize
05
The slide uses a dual-axis chart to visually suggest a causal link between vaccine rollout and reduced mortality.illustrate_case
06
The slide uses a green dashed oval to highlight the incremental FCF generated in 2021 and 2022 relative to the 2020 baseline.quantify_opportunity
07
The chart uses a red vertical arrow to explicitly quantify the 132 percentage point underperformance gap.compare_peers
08
The slide uses a custom bridge visualization to calculate total value lost by combining share price decline and COVID benefit adjustments.show_valuation_bridge
09
The chart highlights LLY and NVO as outliers due to GLP-1 participation. Pfizer is shown in green to distinguish it from the peer group.compare_peers
10
The slide uses a 2x2 grid to categorize the causes of the decline, followed by a summary of the impact on M&A and total market value loss.diagnose_problem
12
The chart uses a dashed red line to indicate the peer median of 46 drugs. Pfizer is highlighted with a dashed green box.compare_peers
13
The slide uses bold and underlined text within the quotes to emphasize key points.cite_precedent
14
The slide uses a series of quotes to establish a narrative of management over-promising or setting a specific expectation regarding R&D pipeline quality.expose_contradiction
15
The slide uses a quote to establish a historical commitment to innovation metrics.cite_precedent
16
The slide is used by Starboard Value to highlight Pfizer's past projections, likely to contrast them with actual performance.expose_contradiction
17
The slide uses a table to document management's stated goals, likely to contrast with later performance or outcomes.cite_precedent
18
The slide uses a screenshot of a Pfizer investor presentation table to point out discrepancies in the company's 'potential blockbuster' pipeline claims.expose_contradiction
19
The slide uses a table from a Pfizer Q1 2019 investor presentation to frame a critique of management's performance.expose_contradiction
20
The slide uses a callout to highlight that royalties were donated, framing the divestment as a negative financial outcome.expose_contradiction
21
The slide uses a screenshot of a news article as primary evidence to support a negative performance claim.cite_precedent
22
The slide uses a visual gap analysis to demonstrate underperformance against a market benchmark.diagnose_problem
23
The slide uses a visual gap analysis to demonstrate that the drug will underperform relative to the blockbuster benchmark.analyze_data
24
The slide uses a direct quote/excerpt from an external research report to support the argument that the vaccine program has been unsuccessful.expose_contradiction
25
The slide uses a screenshot of a press release as primary evidence.cite_precedent
26
The slide uses a series of pull-quotes from financial analysts to build a case for competitive pressure.name_villain
27
The slide uses a screenshot of a press release to provide objective evidence of a clinical trial failure.expose_contradiction
28
The slide uses a screenshot of a press release to establish the clinical efficacy of the drug as a precedent for its commercial success.cite_precedent
29
The slide uses a screenshot of a news headline to provide external validation of a failed drug development project.cite_precedent
30
The slide uses a dialogue format between a GS analyst and the CEO to frame the company's strategic priorities.cite_precedent
31
The slide uses a screenshot of a Pfizer Q1 2019 investor presentation to contrast past promises with current performance.expose_contradiction
32
The slide uses highlighted text within quotes to emphasize key figures ($10B target, $90B market).cite_precedent
33
The slide highlights the gap between internal management targets and external market expectations.analyze_data
34
Uses external analyst quotes to build a case against management's current strategy.expose_contradiction
35
The chart uses a broken axis or truncated scale for the $10,000 bar to fit the visual.analyze_data
36
The slide uses a grouped bar chart to contrast the revenue growth of two specific competitors (LLY and NVO) in the GLP-1 space.compare_peers
38
The chart highlights Pfizer's projected decline compared to positive growth across most peers.compare_peers
39
The chart uses a blue dashed line to indicate the peer median of 51%. Pfizer and Pfizer Excl. COVID are highlighted in red.compare_peers
40
The chart uses a broken axis for the top two bars (NVO, LLY) to accommodate high values.compare_peers
42
The slide uses a bracket to aggregate the total investment value.analyze_data
43
The slide uses a stacked bar chart to visualize the gap between acquisition costs and projected revenue, implying poor capital allocation.expose_contradiction
44
The chart highlights the 'PFE Consolidated Deals (Mgmt)' as an outlier in red compared to the 10-year median.compare_peers
45
The chart uses a stacked bar format to compare company projections against analyst consensus, highlighting a $7.2B discrepancy.analyze_data
46
The chart highlights a 10-year median of 2.4x, with Pfizer's recent deals (3.3x and 5.1x) significantly exceeding this benchmark.analyze_data
47
The slide uses a simple arithmetic bridge to show how different multiples (2.4x, 3.3x, 3.5x) applied to $13.3B in sales result in different implied values, compshow_valuation_bridge
48
Uses a press release excerpt as evidence to critique a corporate acquisition strategy.expose_contradiction
49
Uses a press release excerpt as primary evidence to expose a negative development for the company.expose_contradiction
50
The slide uses external authority to validate a critique of management's capital allocation strategy.expose_contradiction
52
Uses a red dashed box to isolate the 'COVID Benefit' period and a second red dashed box to summarize the success rate statistics.expose_contradiction
53
The chart highlights Pfizer (PFE) and PFE Excl. COVID in red, while peers are in dark blue. A dashed line indicates the peer median of 77%.compare_peers
54
Uses red 'X' icons to visually emphasize the failure to meet expectations.expose_contradiction
55
The slide uses a visual comparison to cast doubt on management's 2023 guidance by contrasting it with the high performance of previous years.expose_contradiction
56
The slide is from a Starboard Value presentation critiquing Pfizer's management. It uses a bar chart to illustrate the expected trajectory of doses sold vs. dosexpose_contradiction
57
The slide uses a red color for the actuals bar and the gap annotation to emphasize the negative performance.expose_contradiction
58
The slide uses red bars to emphasize the negative performance and missed guidance.expose_contradiction
59
Uses a waterfall-style gap annotation to emphasize the magnitude of the earnings miss.diagnose_problem
60
The slide uses external analyst commentary to validate the thesis that management credibility is compromised.expose_contradiction
62
The slide uses a dialogue format between a GS Analyst and the Pfizer CEO to validate the investor's thesis.cite_precedent
63
The chart uses a red vertical arrow to quantify the 132-point underperformance gap.expose_gap
64
The slide uses a competitor's own internal slide as evidence of failure, specifically pointing to discontinued programs (Staphylococcus Aureus, Domagrozumab).expose_contradiction
66
The chart uses a broken axis for the top two performers (NVO, LLY) to accommodate the scale.compare_peers
67
Uses a simple division framework to highlight capital allocation inefficiency.diagnose_problem
68
The slide uses a waterfall chart to frame a critique of management's capital allocation efficiency.show_valuation_bridge
69
Uses a waterfall-style buildup calculation to arrive at an incremental revenue requirement.quantify_opportunity
70
The chart uses a standard waterfall bridge format to reconcile 2023 revenue with a target 2030 revenue figure.show_valuation_bridge
71
Uses a causal link diagram to show the impact of achieving the 38% return target on 2030 financial outcomes.diagnose_problem
72
This is an activist investor presentation slide from Starboard Value.summarize
73
The chart includes a specific data point for 'PFE (Median R&D Efficiency)' at the far right.compare_peers